American Cancer Society Cancer Facts & Figures. special section: ovarian cancer, pp 28–43. 2018. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html. Accessed 30 Dec 2022.

World Health Organization Seventieth World Health Assembly, Geneva, pp. 22–26. 2017. https://www.who.int/news/item/29-05-2017-seventieth-world-health-assembly-update-29-may-2017. Accessed 30 Dec 2022.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.

Article  PubMed  Google Scholar 

Mc Guire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 2016. https://doi.org/10.3945/an.116.012211.

Article  Google Scholar 

How Chemotherapy Drugs Work, American Chemical Society. http://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/how-chemotherapy-drugs-work.html Accessed 27 Jan 2022.

Monte SA, Ethya H, Lang WR. Positive effusion cytology as the initial presentation of malignancy. Acta Cytol. 1987;31:448–52.

CAS  PubMed  Google Scholar 

Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynaecol Oncol. 2002. https://doi.org/10.1006/gyno.2002.6800.

Article  Google Scholar 

Karoo RO, Lloyd TD, Garcea G, Redway HD, Robertson GSR. How valuable is ascetic cytology in the detection and management of malignancy? Postgrad Med J. 2003. https://doi.org/10.1136/pmj.79.931.292.

Article  PubMed  PubMed Central  Google Scholar 

Simojoki M, Santala M, Vuopala S, Kaupilla A. The prognostic value of peritoneal cytology in ovarian cancer. Eur J Gynaecol Oncol. 1999;20:357–60.

CAS  PubMed  Google Scholar 

Ovarian Cancer Stages. https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/staging.html. Accessed 27 Jan 2022.

Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early-stage epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006. https://doi.org/10.1016/j.ygyno.2006.06.013.

Article  PubMed  Google Scholar 

Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Aktinson R. Phase III randomized trial of docetaxel- carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004. https://doi.org/10.1093/jnci/djh323.

Article  PubMed  Google Scholar 

Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst. 2003. https://doi.org/10.1093/jnci/95.2.125.

Article  PubMed  Google Scholar 

Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant Chemotherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95:105–12.

Article  PubMed  Google Scholar 

Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006. https://doi.org/10.1056/NEJMoa052985.

Article  PubMed  Google Scholar 

Walker JL. Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. Gynecol Oncol. 2009. https://doi.org/10.1016/j.ygyno.2009.01.007.

Article  PubMed  PubMed Central  Google Scholar 

Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally respected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2003. https://doi.org/10.1200/jco.2003.02.153.

Article  PubMed  Google Scholar 

Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012. https://doi.org/10.1038/bjc.2012.307.

Article  PubMed  PubMed Central  Google Scholar 

Parmar MK, Ledermann JA, Colombo N, du Bois A, Delalove JF, Kristensen GB, et al. ICON and Collaborators Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003. https://doi.org/10.1016/s0140-6736(03)13718-x.

Article  PubMed  Google Scholar 

Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial. Lancet. 2009. https://doi.org/10.1016/s0140-6736(09)61157-0.

Article  PubMed  Google Scholar 

Pfisterer J, Plante M, Vergote I, du Boise A, Hirte H, Lacave AJ, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006. https://doi.org/10.1200/jco.2006.06.0913.

Article  PubMed  Google Scholar 

Du Bois A, Luck HJ, Pfisterer J, Schroeder W, Blohmer JU, Kimmig R, et al. Second-line carboplatin and gemcitabin in platinum sensitive ovarian cancer-a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) ovarian cancer study group. Ann Oncol. 2001. https://doi.org/10.1023/a:1011605008922.

Article  PubMed  Google Scholar 

Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007. https://doi.org/10.1200/jco.2007.11.5345.

Article  PubMed  Google Scholar 

Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum- sensitive recurrent epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012. https://doi.org/10.1200/jco.2012.42.0505.

Article  PubMed  PubMed Central  Google Scholar 

Gordan AN, Tonda M, Sun S, Rackoff W. Doxil Study: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004. https://doi.org/10.1016/j.ygyno.2004.07.011.

Article  Google Scholar 

Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007. https://doi.org/10.1200/jco.2006.09.6735.

Article  PubMed  Google Scholar 

Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008. https://doi.org/10.1200/jco.2007.13.6606.

Article  PubMed  Google Scholar 

Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol. 2003. https://doi.org/10.1016/s0090-8258(03)00399-8.

Article  PubMed  Google Scholar 

Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum resistant ovarian cancer: a ransomized multicentre phase II trial of the North-Eastern German society of gynecological oncology ovarian cancer study group. J Clin Oncol. 2011. https://doi.org/10.1200/JCO.2009.27.8911.

Article  PubMed  Google Scholar 

Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Gynecologic Oncology Group. Phase II trial of weekly paclitaxel (80mg/m2) in platinum and paclitaxel-resistant ovarian cancer and primary peritoneal ovarian cancers: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006. https://doi.org/10.1016/j.ygyno.2005.10.036.

Article  PubMed  PubMed Central  Google Scholar 

Bruzzone M, Catsafados E, Miglietta L, Amoroso D, Pedulla F, Giannessi PG, et al. Salvage chemotherapy with paclitaxel-resistant advanced ovarian cancer patients. Oncology. 1996;53:349–53.

Article  CAS  PubMed  Google Scholar 

Gore ME, Levy V, Rustin G, Perren T, Calvert AH, Earl H, et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer. 1995. https://doi.org/10.1038/bjc.1995.453.

Article  PubMed  PubMed Central  Google Scholar 

Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes E, Steger M, Nelson-Taylor T, et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol. 2000. https://doi.org/10.1200/jco.2000.18.14.2733.

Article  PubMed  Google Scholar 

Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, Degeest K, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003. https://doi.org/10.1016/s0090-8258(02)00091-4.

Article  PubMed  Google Scholar 

Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian cancer carcinoma: a Gynecologic oncology Group study. J Clin Oncol. 1998. https://doi.org/10.1200/jco.1998.16.2.405.

Article  PubMed  Google Scholar 

Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum- resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011. https://doi.org/10.1016/j.ygyno.2011.03.036.

Article  PubMed  PubMed Central  Google Scholar 

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014. https://doi.org/10.1200/jco.2013.51.4489.

Article  PubMed  PubMed Central  Google Scholar 

Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizummab in patient with platinum-resistant ovarian cancer. J Clin Oncol. 2017;25:5180–6.

Article  Google Scholar 

McGonigel KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Greer BE. Combined weekly topotecan and biweekly bevacizummab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer. 2017. https://doi.org/10.1002/cncr.25967.

Article  Google Scholar 

Fader AN, Von Gruenigen V, Gibbons H, Abushahin F, Starks D, Markman M. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol. 2008. https://doi.org/10.1016/j.ygyno.2008.01.001.

Article  PubMed